APA (7th ed.) Citation

McDorman, K. S., Bennet, B. M., Colman, K., Fikes, J. D., Keirstead, N. D., Lanning, L., . . . Geoly, F. J. (2024). Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies. Toxicologic Pathology, 52(2/3), 138. https://doi.org/10.1177/01926233241248654

Chicago Style (17th ed.) Citation

McDorman, Kevin S., et al. "Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies." Toxicologic Pathology 52, no. 2/3 (2024): 138. https://doi.org/10.1177/01926233241248654.

MLA (9th ed.) Citation

McDorman, Kevin S., et al. "Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies." Toxicologic Pathology, vol. 52, no. 2/3, 2024, p. 138, https://doi.org/10.1177/01926233241248654.